Raptor Pharmaceutical Presents Results from Meta-Analysis Demonstrating Efficacy of QUINSAIR™ Comparable to Other Approved, Inhaled Antibiotics in Cystic Fibrosis Patients
September 07, 2016 03:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Present Data on QUINSAIR™ and Other Inhaled Antibiotics at the ERS International Congress
August 24, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical Voted A “Best Places to Work” Company in the North San Francisco Bay Area
August 18, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) announced today that it was named among the top workplaces in the North Bay in the 11th Annual North Bay...
Raptor Pharmaceutical to Participate in the 2016 JMP Life Sciences Conference
June 14, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 14, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference:Julie Anne Smith, President...
Raptor Pharmaceutical Announces Presentation of New Data Analyses from a Phase 3 Study of QUINSAIR™ at the 39th European Cystic Fibrosis Conference
June 10, 2016 08:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 10, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Present Data on QUINSAIR™ at European Cystic Fibrosis Conference
June 07, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP), a biopharmaceutical company developing and commercializing transformative treatments for rare diseases,...
Raptor Pharmaceutical to Hold First Quarter 2016 Financial Results Conference Call and Webcast on Thursday, May 5, 2016, at 4:30 p.m. ET
April 28, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release first quarter 2016 financial results on Thursday, May 5,...
Raptor’s PROCYSBI® New Drug Submission Accepted by Health Canada with Priority Review
March 21, 2016 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., March 21, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI®...
Raptor Pharmaceutical to Hold Fourth Quarter and Full Year 2015 Financial Results Conference Call and Webcast on Thursday, February 25, 2016, at 4:30 p.m. ET
February 18, 2016 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the company will release fourth quarter and full year 2015 financial results on...
Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
January 25, 2016 07:05 ET
|
Raptor Pharmaceutical Inc
Five Patents for PROCYSBI Now Listed in FDA Orange Book Orphan Drug Exclusivity Extended in Nephropathic Cystinosis Patients 2-6 Years Old NOVATO, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Raptor...